2-氨基-6-吡啶甲醇 | 79651-64-2

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-氨基-6-吡啶甲醇
• 中文别名: 2-氨基吡啶-6-甲醇；6-氨基-2-吡啶甲醇
• 英文名称: (6-Amino-pyridin-2-yl)-methanol
• 英文别名: 2-amino-6-hydroxymethylpyridine；(6-Aminopyridin-2-yl)methanol
• CAS: 79651-64-2
• 化学式: C₆H₈N₂O
• 分子量: 124.142
• InChiKey: YGMPMXTWKROXPP-UHFFFAOYSA-N

物化性质

• 熔点：
  70℃
• 沸点：
  299℃
• 密度：
  1.257
• 闪点：
  134℃
• 溶解度：
  微溶于水。

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  59.1
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  室温且干燥

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
(6-Aminopyridin-2-yl)methanol
Product Name:
Synonyms: 2-Aminopyridine-6-methanol

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
(6-Aminopyridin-2-yl)methanol
Ingredient name:
CAS number: 79651-64-2

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C6H8N2O
Molecular weight: 124.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氨基-6-吡啶甲醇 在 咪唑 、 4-二甲氨基吡啶 、 四丁基氟化铵 、 lithium hydroxide 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 44.0h， 生成 6-(羟基甲基)吡啶-2-氨基甲酸叔丁酯
  参考文献：
  名称：

  [EN] AGRICULTURAL CHEMICALS
  [FR] SUBSTANCES AGROCHIMIQUES

  摘要：

  本发明涉及在农业领域作为杀菌剂使用的化合物。

  公开号：

  WO2017178819A1
• 作为产物：
  描述：

  6-乙酰氨基吡啶羧酸 在 sodium tetrahydroborate 、 硫酸 、 calcium chloride 作用下， 以 乙醇 为溶剂， 反应 2.0h， 生成 2-氨基-6-吡啶甲醇
  参考文献：
  名称：

  金属控制的动态分子镊子：金属离子配位的设计、合成和自组装

  摘要：

  将可控动态特征引入合成受体代表了迈向“智能”自适应纳米设备的一步。我们在此报告了我们对动态分子镊子构建的研究，其中底物的结合通过金属离子配位诱导的受体形状转换进行变构控制。使用一维、二维核磁共振光谱和 X 射线晶体学来鉴定生成的金属超分子实体的性质。分子镊子支架上大芳烃萘二亚胺部分的存在强烈影响其配位驱动的自组装。发现这些额外的堆积相互作用导致同质复合物的协同形成、异质复合物的自分类组装以及非配位芳香客体的结合。

  DOI：

  10.1002/ejic.200901262

文献信息

• Haloguanidine compounds, pharmaceutical compositions and methods of use
  申请人：ICI Americas Inc.

  公开号：US04362728A1

  公开（公告）日：1982-12-07

  Compounds useful for inhibiting gastric acid secretion and for the treatment of peptic ulcers caused or exacerbated by gastric acidity having the following formula (I): ##STR1## in which R.sup.1 and R.sup.2, are H, C.sub.1-10 alkyl, C.sub.3-8 cycloalkyl or cycloalkylalkyl in which the alkyl part is C.sub.1-6 and the cycloalkyl part is C.sub.3-8, each of the alkyl, cycloalkyl and cycloalkylalkyls being optionally substituted by one or more halogens selected from F, Cl and Br, provided that at least one of R.sup.1 and R.sup.2 is a halogen substituted alkyl, cycloalkyl or cycloalkylalkyl and provided that there is no halogen substituent on the carbon directly attached to the nitrogen; and X, m, Y, n and R.sup.3 are as described in the specification; and the pharmaceutically-acceptable acid-addition salts thereof. Processes for producing compounds of formula (I), pharmaceutical compositions containing them, methods of utilizing such compositions and intermediates useful for synthesizing compounds of formula (I) are also described.

  用于抑制胃酸分泌和治疗由胃酸引起或加重的消化性溃疡的化合物具有以下结构式（I）：##STR1##其中R.sup.1和R.sup.2为H，C.sub.1-10烷基，C.sub.3-8环烷基或环烷基烷基，其中烷基部分为C.sub.1-6，环烷基部分为C.sub.3-8，每个烷基，环烷基和环烷基烷基可选择地被来自F、Cl和Br的一个或多个卤素取代，前提是R.sup.1和R.sup.2中至少有一个是卤素取代的烷基，环烷基或环烷基烷基，并且直接连接到氮的碳上没有卤素取代物；X，m，Y，n和R.sup.3如规范中所述；以及其药用可接受的酸加盐。还描述了制备结构式（I）化合物的方法，含有它们的药物组合物，利用这种组合物的方法以及用于合成结构式（I）化合物的中间体。
• Enantioselective Hydrogenation of Imidazo[1,2-<i>a</i> ]pyridines
  作者：Christoph Schlepphorst、Mario P. Wiesenfeldt、Frank Glorius

  DOI：10.1002/chem.201705370

  日期：2018.1.9

  of tetrahydroimidazo[1,2‐a]pyridines by direct hydrogenation was achieved using a ruthenium/N‐heterocyclic carbene (NHC) catalyst. The reaction forgoes the need for protecting or activating groups, proceeds with complete regioselectivity, good to excellent yields, enantiomeric ratios of up to 98:2, and tolerates a broad range of functional groups. 5,6,7,8‐Tetrahydroimidazo[1,2‐a]pyridines, which are

  使用钌/ N-杂环卡宾（NHC）催化剂，通过直接氢化完成对四氢咪唑并[1,2- a ]吡啶的对映选择性合成。该反应放弃了对保护基团或活化基团的需要，以完全的区域选择性，良好至优异的产率，高达98：2的对映体比例进行，并且耐受宽泛的官能团。5,6,7,8-四氢咪唑并[1,2一]吡啶，其在许多生物活性分子中发现，直接通过该方法获得的，其适用性是由几个功能性分子的（正式）合成证明。
• [EN] QUINAZOLINE DERIVATIVES FOR USE AGAINST CANCER<br/>[FR] DERIVES DE QUINAZOLINE A UTILISER CONTRE LE CANCER
  申请人：ASTRAZENECA AB

  公开号：WO2006040526A1

  公开（公告）日：2006-04-20

  The invention concerns quinazoline derivatives of Formula (I) or a pharmaceutically-acceptable salt, solvate or pro-drug thereof, wherein each of p, R1, q, R2, R3, R4, R5, Ring A, X1, R6, r and R7 has any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders or in the treatment of disease states associated with angiogenesis and/or vascular permeability.

  本发明涉及式(I)喹唑啉衍生物或其药物可接受的盐、溶剂化物或前药，其中p、R1、q、R2、R3、R4、R5、环A、X1、R6、r和R7各自具有说明书中定义的任何含义；其制备方法、含有它们的药物组合物以及它们在制造用于治疗细胞增殖障碍或治疗与血管生成和/或血管通透性相关的疾病状态的药物中的应用。
• [EN] AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS<br/>[FR] AZOLOPYRIMIDINE POUR LE TRAITEMENT DE TROUBLES LIÉS AU CANCER
  申请人：ARCUS BIOSCIENCES INC

  公开号：WO2018136700A1

  公开（公告）日：2018-07-26

  Compound that is an inhibitor of at least one of the A2A and A2B adenosine receptors, and compositions containing the compound and methods for synthesizing the compound, are described herein. The use of such compound and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine A2A receptor and/or the adenosine A2B receptor.

  本文描述了一种至少抑制A2A和A2B腺苷受体中至少一种的化合物，以及含有该化合物的组合物和合成该化合物的方法。利用这种化合物和组合物治疗各种疾病、紊乱和病况，包括至少部分由腺苷A2A受体和/或腺苷A2B受体介导的癌症和免疫相关紊乱。
• <i>N</i>-bromosuccinimide reactions of some heterocycles in the presence or absence of water: An overview of ring versus side chain bromination for the synthesis of important brominated heterocyclic synthons
  作者：Shyamaprosad Goswami、Kumaresh Ghosh、Reshmi Mukherjee、Avijit Kumar Adak、Ajit Kumar Mahapatra

  DOI：10.1002/jhet.5570380125

  日期：2001.1

  Reactions of various heterocycles 1–6 with N-bromosuccinimide in the presence or absence of water have been studied for side chain versus ring bromination to afford some new and important heterocyclic synthons. Interestingly, the N-bromosuccinimide reaction in the presence of perchloric acid, a new condition, affords exclusively the new dibromo aminopicoline 1f, which is not obtained by other presently

  对于侧链与环溴化反应，研究了各种杂环1-6与N-溴琥珀酰亚胺在有水或无水条件下的反应，以提供一些新的重要的杂环合成子。有趣的是，在高氯酸存在下的N-溴琥珀酰亚胺反应（一种新条件）仅提供了新的二溴氨基吡啶1f，这是目前其他研究方法无法获得的。